Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

India Plans New Clinical Trial Laws

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - India plans to change laws to give the government power to crack down on firms carrying out unethical drug trials as it seeks to become a global hub for clinical testing, according to a health ministry official

You may also be interested in...



Indian Clinical Research Industry Divided Over Mandatory Registration Of Clinical Trials From June 15

NEW DELHI - As the June 15 deadline approaches for India's mandatory registration of clinical trials in a publicly accessible library, the industry is bracing itself to put trial details online with mixed reactions

Indian Clinical Research Industry Divided Over Mandatory Registration Of Clinical Trials From June 15

NEW DELHI - As the June 15 deadline approaches for India's mandatory registration of clinical trials in a publicly accessible library, the industry is bracing itself to put trial details online with mixed reactions

GVK Bio Says It Found No Link Between Wyeth Prevnar Vaccine And Child Death; Inspectors Did Not Check Documentation

MUMBAI - GVK Biosciences, the clinical research organization responsible for site monitoring for Wyeth's Prevnar vaccine trial in India has said it found no linkage between the administered vaccine and the death of a child, who died during the course of the clinical trials at Bangalore's St. John's Hospital's National Academy of Health Sciences

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC069936

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel